8. Immunomodulators and antineoplastics

8.2. Antineoplastics and supportive medicines

8.2.1. Cytotoxic medicines

Carboplatin

**Indication**
Retinoblastoma (ICD11 code: 2D52.2)

**INN**
Carboplatin

**Medicine type**
Chemical agent

**List type**
Complementary

**Formulations**
Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

**EML status history**
First added in 2009 (TRS 958)
Changed in 2015 (TRS 994)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions
Read more about patents.

**Tags**
Cancer

**Wikipedia**
Carboplatin

**DrugBank**
Carboplatin

**Summary of evidence and Expert Committee recommendations**

Carboplatin was originally added to the complementary list of the EML in 2009 as a treatment of advanced ovarian cancer. In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for carboplatin on the complementary list of the EML and EMLc for use in treatment protocols for retinoblastoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's consideration of the treatment protocols for retinoblastoma is attached.